In particular, engineered T cells with a CAR directed to CD19 or B-cell maturation antigen (BCMA) have become integral in the treatment of relapsed/refractory B-cell leukemia and lymphoma, as well as multiple myeloma, stated in [1,2,3]. This evidence concerns the gene CD19 and AL amyloidosis.